Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome

Journal of Pediatric Endocrinology and Metabolism

Volumn 20, Issue 1, 2007, Pages 41-51

  Littlejohn, Elizabeth E ^a   Weiss, Roy E ^b   Deplewski, Dianne ^a   Edidin, Deborah V ^a   Rosenfield, Robert ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Insulin resistance; Obesity; Polycystic ovary syndrome; Precocious puberty; Pseudo acromegaly; Pseudo Cushing's syndrome

Indexed keywords

ACROMEGALY; ARTICLE; BODY MASS; CASE REPORT; CHILD CARE; CLINICAL FEATURE; CUSHINGOID SYNDROME; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENDOCRINE FUNCTION TEST; FEMALE; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LABORATORY TEST; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OLIGOMENORRHEA; ONSET AGE; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; SCHOOL CHILD; SECONDARY AMENORRHEA; ADOLESCENT; CHILD; CUSHING SYNDROME; HYPERINSULINISM; PATHOLOGY; PRECOCIOUS PUBERTY; TIME;

ADOLESCENT; CHILD; CUSHING SYNDROME; FEMALE; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; PUBERTY, PRECOCIOUS; TIME FACTORS;

EID: 33947505766     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2007.20.1.41     Document Type: Article

References (66)

1. Flegal KM, Ogden CL, Wei R, Kuczmarski RL, Johnson CL. Prevalence of overweight in US children: comparison of US growth charts from the Centers for Disease Control and Prevention with other reference values for body mass index. Am J Clin Nutr 2001; 73: 1086-1093.
2. Kral J. Preventing and treating obesity in girls and young women to curb the epidemic. Obes Res 2004; 12: 1539-1546.
3. Apter D, Bützow G, Laughlin A, Yen SSC. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab 1995; 80: 2966-2973.
4. Rosenfield RL, Ghai K, Ehrmann DA, Barnes RB. Diagnosis of polycystic ovary syndrome in adolescence. Comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab 2000; 13 (Suppl 5): 1285-1289.
5. Silfen M, Denburg M, Manibo A, Lobo R, Jaffe R, Ferin M, Levine LS, Oberfield SE. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between non-obese and obese adolescents. J Clin Endocrinol Metab 2003; 88: 4682-4688.
6. Trent M, Austin SB, Rich M, Gordon CM. Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life. Ambul Pediatr 2005; 5: 107-111.
7. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749.
8. Rosenfield RL. Polycystic ovary syndrome and insulin-resistant hyperinsulinemia. J Am Acad Dermatol 2001; 45: S095-104.
9. Baumann E, Rosenfield R. Polycystic ovary syndrome in adolescence. Endocrinologist 2002; 12: 333-348.
10. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
11. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003; 52: 908-915.
12. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82: 893-902.
13. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236.
14. Amato P, Simpson JL. The genetics of polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004; 18: 707-718.
15. Barnes RB, Rosenfield RL, Ehrmann DA, Cara JF, Cuttler L, Levitsky LL, Rosenthal IM. Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994; 79: 1328-1333.
16. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol 2002; 174: 1-5.
17. Ibáñez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism: relation to reduced fetal growth. J Clin Endocrinol Metab 1998; 83: 3558-3562.
18. Ibáñez L, de Zegher F, Potau N. Anovulation after precocious pubarche: early markers and time course in adolescence. J Clin Endocrinol Metab 1999; 84: 2691-2695.
19. Newell-Price J. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19: 647-672.
20. Moro M, Putignano P, Losa M, Invitti C, Maraschini C, Cavagnini F. The desmopressin test in the differential diagnosis between Cushing's disease and pseudo-Cushing states. J Clin Endocrinol Metab 2000; 85: 3569-3574.
21. Dib K, Whitehead JP, Humphreys PJ, Soos MA, Baynes KC, Kumar S, Harvey T, O'Rahilly S. Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly. A disorder characterized by selective postreceptor insulin resistance. J Clin Invest 1998; 101: 1111-1120.
22. Flier JS, Moller DE, Moses AC, O'Rahilly S, Chaiken RL, Grigorescu F, Elahi D, Kahn BB, Weinreb JE, Eastman R. Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab 1993; 76: 1533-1541.
23. Low L, Chernausek S, Sperling M. Acromegaloid patients with type A insulin resistance: parallel defects in insulin and insulin-like growth factor-I receptors and biological responses in cultured fibroblasts. J Clin Endocrinol Metab 1989; 69: 329-337.
24. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992; 327: 157-162.
25. Grundy S, Brewer HJ, Cleeman J, Smith SJ, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific issues Related to Definition. Circulation 2004; 109: 433-438.
26. Arvat E, Di Vito L, Lanfranco F, Maccario M, Baffoni C, Rossetto R, Aimaretti G, Camanni F, Ghigo E. Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. J Clin Endocrinol Metab 2000; 85: 3141-3146.
27. Rosenfield RL, Perovic N, Ehrmann DA, Barnes RB. Acute hormonal responses to the gonadotropin releasing hormone agonist leuprolide: dose-response studies and comparison to nafarelin. J Clin Endocrinol Metab 1996; 81: 3408-3411.
28. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140: 815.
29. Venturoli S, Porcu E, Fabbri R, Pluchinotta V, Ruggeri S, Macrelli S, Paradisi R, Flamigni C. Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr Res 1995; 38: 974-980.
30. Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens J, Haseltine F, Merriam G, eds. Polycystic Ovary Syndrome. Cambridge, MA: Blackwell Scientific Publications, 1992; 377-384.
31. Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, Nieman LK, Post RM, Pickar D, Gallucci W, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med 1986; 314: 1329-1335.
32. Cunningham J, Buxton O, Weiss R. Circadian variation in Cushing's disease and pseudo-Cushing states by analysis of F and ACTH pulsatility. J Endocrinol Invest 2002; 25: 791-799.
33. Chestnut RE, Quarmby V. Evaluation of total IGF-I assay methods using samples from type I and type II diabetic patients. J Imnunol Meth 2002; 259: 11-24.
34. Morgan C, Lazarow A. Immunoassay of insulin: two antibody system. Plasma insulin levels of normal, subdiabetic, and diabetic rats. Diabetes 1963; 12: 115-126.
35. Matthews DR. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
36. Root A, Moshang TJ. Evolution of the hyperandrogenism/polycystic ovarian syndrome from isosexual precocious puberty: report of two cases. Am J Obstet Gynecol 1984; 149: 763.
37. Cisternino M, Pasquino A, Bozzola M, Balducci R, Lorini R, Pucarelli I, Segni M, Severi F. Final height attainment and gonadal function in girls with precocious puberty treated with cyproterone acetate. Horm Res 1992; 37: 86-90.
38. Adashi EY, Hsueh AJ, Yen SS. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 1981; 108: 1441-1449.
39. Xia YX, Weiss JM, Polack S, Diedrich K, Ortmann O. Interactions of insulin-like growth factor-I, insulin and estradiol with GnRH-stimulated luteinizing hormone release from female rat gonadotrophs. Eur J Endocrinol 2001; 144: 73-79.
40. Unger JW, Lange W. Insulin receptors in the pituitary gland: morphological evidence for influence on opioid peptide-synthesizing cells. Cell Tissue Res 1997; 288: 471-483.
41. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122-2125.
42. Burks DJ, Font de Mora JF, Schubert M, Withers DJ, Myers MG, Towery HH, et al. Altamuro SL, Flint CL, White MF. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 2000; 407: 377-382.
43. Kumar S, Durrington PN, O'Rahilly S, Laing I, Humphreys PJ, Olukoga AO, Bhatnagar D, Mackness MI, Davis JR, Boulton AJ. Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudo-acromegaly. J Clin Endocrinol Metab 1996; 81: 3465-3468.
44. Fukunaga Y, Minamikawa J, Inoue D, Koshiyama H, Fujisawa I. Pseudoacromegaly and hyperinsulinemia: a possibility of premature atherosclerosis? J Clin Endocrinol Metab 1997; 82: 3515-3516.
45. Saltiel AR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
46. Sinha R, Fisch G, Teague B, Tamborlane W, Banyas B, Allen K, Savoye M, Rieger V, Taksali S, Barbetta G, Sherwin RS, Caprio S. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002; 346: 802-810.
47. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23: 295-301.
48. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003; 157: 821-827.
49. Kausch C, Bergemann C, Hamann A, Matthaei S. Insulin-mediated pseudoacromegaly in a patient with severe insulin resistance: association of defective insulin-stimulated glucose transport with impaired phosphatidylinositol 3-kinase activity in fibroblasts. Exp Clin Endocrinol Diabetes 1999; 107: 148-154.
50. Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84: 3110-3116.
51. Poretsky L, Seto-Young D, Shrestha A, Dhillon S, Mirjany M, Liu HC, Yih MC, Rosenwaks Z. Phosphatidyl-inositol-3 kinase-independent insulin action pathway(s) in the human ovary. J Clin Endocrinol Metab 2001; 86: 3115-3119.
52. Van Wyk J, Graves D, Casella S, Jacobs S. Evidence from monoclonal antibody studies that insulin stimulates deoxyribonucleic acid synthesis through the type I somatomedin receptor. J Clin Endocrinol Metab 1985; 61: 639-643.
53. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001; 281: E392-399.
54. Tomlinson J, Draper N, Mackie J, Johnson A, Holder G, Wood P, Stewart PM. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. J Clin Endocrinol Metab 2002; 87: 57-62.
55. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone D, Johnson O, Walker BR. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418-1421.
56. Masuzaki H, Paterson J, Shinyama H, Morton N, Mullins J, Seckl J, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170.
57. Handoko K, Yang K, Strutt B, Khalil W, Killinger D. Insulin attenuates the stimulatory effects of tumor necrosis factor alpha on 11beta-hydroxysteroid dehydrogenase 1 in human adipose stromal cells. J Steroid Biochem Mol Biol 2000; 72: 163-168.
58. Travers SH, Jeffers BW, Eckel RH. Insulin resistance during puberty and future fat accumulation. J Clin Endocrinol Metab 2002; 87: 3814-3818.
59. Maffeis C. Insulin resistance and the persistence of obesity from childhood into adulthood. J Clin Endocrinol Metab 2002; 87: 71-76.
60. Odaleye O, de Courten M, Pettitt D, Ravussin E. Fasting hyperinsulinemia is a predictor of increased body weight gain and obesity in Pima Indian children. Diabetes 1997; 46: 1341-1345.
61. Glickman SP, Rosenfield RL, Bergenstal RM, Helke J. Multiple androgenic abnormalities, including elevated free testosterone, in hyperprolactinemic women. J Clin Endocrinol Metab 1982; 55: 251.
62. Noczynska A, Wasikowa R. Hyperprolactinemia in children during the peripubertal period-personal observations. J Pediatr Endocrinol Metab 2004; 17: 1399-1404.
63. Prelevic G, Wurzburger M, Peric L. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome. J Endocrinol Invest 1987; 10: 389-395.
64. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
65. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists: Number 41, December 2002. Obstet Gynecol 2002; 100: 1389-1402.
66. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995; 16: 322-353.